160% NSCLC enrollment. Multi-country. Research-only sites. Solid tumor recruitment is one of the most unpredictable areas in clinical trials. Phase...
READ MORE4 active melanoma studies. 167% enrollment. One network. Finding treatment-naive melanoma patients in Western Europe and the US is getting harder e...
READ MOREWhen enrollment exceeds 300% of target, it's infrastructure. At ARENSIA, we own and operate 15 research-only clinics across 8 countries. No sha...
READ MORESome teams perform well when conditions are ideal. Others redefine what operational excellence really means. ARENSIA Ukraine team has consistent...
READ MOREARENSIA is growing within ophthalmology, bringing a new level of precision to the field. We have randomized the first patient in a highly sophistic...
READ MOREARENSIA Moldova is honored to receive the Monique Ackermann Award from the European Society of Oncology Pharmacy (ESOP). This recognition supports the...
READ MOREThe best innovations do not add complexity. They remove it. At ARENSIA, we designed a clinical research model built for speed, precision, and perfo...
READ MOREOur team was at EULAR. So were we. On the track — 6 months ahead of schedule. While the rheumatology world gathered in London, our clinics ke...
READ MOREWe were pleased to contribute to the “Healthy Ukraine 2030” forum through the participation of Dr. Evgeny Levenko, Country Manager of AREN...
READ MOREARENSIA is revving up for OCT UK & Ireland 2026 in London, 9–10 June! On Day 1, Dr. Claudia Hesselmann, PhD, Founder & CEO of ARENSIA...
READ MOREWe are pleased to share that Dr. Nelli Ghicavii, Aurelia Siranu, and Megan Morris will represent ARENSIA at the American College of Cardiology Annual ...
READ MOREWe’ve expanded into one of Latin America’s most dynamic clinical research hubs, bringing faster access to innovative therapies where it ma...
READ MORE